Charlotta Nilsson

Publications
CV
Public outreach and news

Articles

Article: MICROBIAL CELL FACTORIES. 2024;23(1):39
Stable expression of HIV-1 MPER extended epitope on the surface of the recombinant probiotic bacteria Escherichia Coli Nissle 1917 using CRISPR/Cas9
Ninyio N; Schmitt K; Sergon G; Nilsson C; Andersson S; Scherbak N
Article: PLOS ONE. 2024;19(2):e0298912
Laboratory-based evaluation of the 4th-generation Alere™ HIV Combo rapid point-of-care test
Manjate A; Nilsson C; Axelsson M; Lindroth S; Sirbu D; Sacarlal J; Andersson S; Unemo M
Article: JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (1999). 2022;91(5):439-448
The Prevalence, Incidence, and Risk Factors for HIV Among Female Sex Workers-A Cohort Being Prepared for a Phase IIb HIV Vaccine Trial in Dar es Salaam, Tanzania
Faini D; Msafiri F; Munseri P; Bakari M; Lyamuya E; Sandstrom E; Biberfeld G; Nilsson C; Hanson C; Aboud S
Article: VACCINES. 2022;10(7):1062
Vaccine-Induced Seroreactivity Impacts the Accuracy of HIV Testing Algorithms in Sub-Saharan Africa: An Exploratory Study
Msafiri F; Manjate A; Lindroth S; Tembe N; Chissumba RM; Cumbane V; Jani I; Aboud S; Lyamuya E; Andersson S; Nilsson C
Article: VACCINES. 2022;10(3):359
Duration of SARS-CoV-2 Immune Responses Up to Six Months Following Homologous or Heterologous Primary Immunization with ChAdOx1 nCoV-19 and BNT162b2 mRNA Vaccines
Marking U; Havervall S; Greilert-Norin N; Ng H; Blom K; Nilsson P; Phillipson M; Hober S; Nilsson C; Mangsbo S; Christ W; Klingstrom J; Gordon M; Aberg M; Thalin C
Article: FRONTIERS IN IMMUNOLOGY. 2022;13:1075606
Systematic comparison of HIV-1 Envelope-specific IgG responses induced by different vaccination regimens: Can we steer IgG recognition towards regions of viral vulnerability?
Horvath A; Rogers L; Pollakis G; Baranov O; Pieroth N; Joseph S; Chachage M; Heitzer A; Maganga L; Msafiri F; Joachim A; Viegas E; Eller L-A; Kibuuka H; Rerks-Ngarm S; Pitisuttithum P; Nitayapan S; Dhitavat J; Premsri N; Fidler S; Shattock RJJ; Robb ML; Weber J; McCormack S; Munseri PJ; Lyamuya E; Nilsson C; Kroidl A; Hoelscher M; Wagner R; Geldmacher C; Held K
Article: SCIENTIFIC REPORTS. 2021;11(1):7614
Evaluation of 11 SARS-CoV-2 antibody tests by using samples from patients with defined IgG antibody titers
Lagerqvist N; Maleki KT; Verner-Carlsson J; Olausson M; Dillner J; Bystrom JW; Monsen T; Forsell M; Eriksson J; Bogdanovic G; Muschiol S; Ljunggren J; Repo J; Kjerstadius T; Muradrasoli S; Brytting M; Bjorndal AS; Akerlund T; Nilsson C; Klingstrom J
Article: VACCINES. 2020;8(4):E681-681
Frequent and Durable Anti-HIV Envelope VIV2 IgG Responses Induced by HIV-1 DNA Priming and HIV-MVA Boosting in Healthy Tanzanian Volunteers
Joachim A; Msafiri F; Onkar S; Munseri P; Aboud S; Lyamuya EF; Bakari M; Billings E; Robb ML; Wahren B; Mhalu FS; Sandstrom E; Rao M; Nilsson C; Biberfeld G
Article: MICROORGANISMS. 2020;8(11):E1722-1722
Frequent Anti-V1V2 Responses Induced by HIV-DNA Followed by HIV-MVA with or without CN54rgp140/GLA-AF in Healthy African Volunteers
Msafiri F; Joachim A; Held K; Nadai Y; Chissumba RM; Geldmacher C; Aboud S; Stohr W; Viegas E; Kroidl A; Bakari M; Munseri PJ; Wahren B; Sandstrom E; Robb ML; McCormack S; Joseph S; Jani I; Ferrari G; Rao M; Biberfeld G; Lyamuya E; Nilsson C
Article: FRONTIERS IN IMMUNOLOGY. 2020;11:719
Induction of Identical IgG HIV-1 Envelope Epitope Recognition Patterns After Initial HIVIS-DNA/MVA-CMDR Immunization and a Late MVA-CMDR Boost
Joachim A; Ahmed MIM; Pollakis G; Rogers L; Hoffmann VS; Munseri P; Aboud S; Lyamuya EF; Bakari M; Robb ML; Wahren B; Sandstrom E; Nilsson C; Biberfeld G; Geldmacher C; Held K
Article: IMMUNOBIOLOGY. 2018;223(12):792-801
Regulatory T cell abundance and activation status before and after priming with HIVIS-DNA and boosting with MVA-HIV/rgp140/GLA-AF may impact the magnitude of the vaccine-induced immune responses
Chissumba RM; Luciano A; Namalango E; Bauer A; Bhatt N; Wahren B; Nilsson C; Geldmacher C; Scarlatti G; Jani I; Kestens L
Article: AIDS RESEARCH AND HUMAN RETROVIRUSES. 2018;34(2):193-205
Intradermal HIV-1 DNA Immunization Using Needle-Free Zetajet Injection Followed by HIV-Modified Vaccinia Virus Ankara Vaccination Is Safe and Immunogenic in Mozambican Young Adults: A Phase I Randomized Controlled Trial
Viegas EO; Tembe N; Nilsson C; Meggi B; Maueia C; Augusto O; Stout R; Scarlatti G; Ferrari G; Earl PL; Wahren B; Andersson S; Robb ML; Osman N; Biberfeld G; Jani I; Sandstrom E
Article: PLOS ONE. 2018;13(11):e0206838
Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140/GLA vaccines in a phase II randomized factorial trial design
Viegas EO; Kroidl A; Munseri PJ; Missanga M; Nilsson C; Tembe N; Bauer A; Joachim A; Joseph S; Mann P; Geldmacher C; Fleck S; Stohr W; Scarlatti G; Aboud S; Bakari M; Maboko L; Hoelscher M; Wahren B; Robb ML; Weber J; McCormack S; Biberfeld G; Jani IV; Sandstrom E; Lyamuya E
Article: JOURNAL OF VIROLOGY. 2017;91(18):e00730-e00717
Preferential Targeting of Conserved Gag Regions after Vaccination with a Heterologous DNA Prime-Modified Vaccinia Virus Ankara Boost HIV-1 Vaccine Regimen
Bauer A; Podola L; Mann P; Missanga M; Haule A; Sudi L; Nilsson C; Kaluwa B; Lueer C; Mwakatima M; Munseri PJ; Maboko L; Robb ML; Tovanabutra S; Kijak G; Marovich M; McCormack S; Joseph S; Lyamuya E; Wahren B; Sandstrom E; Biberfeld G; Hoelscher M; Bakari M; Kroidl A; Geldmacher C
Article: AIDS RESEARCH AND HUMAN RETROVIRUSES. 2017;33(8):880-888
Three-Year Durability of Immune Responses Induced by HIV-DNA and HIV-Modified Vaccinia Virus Ankara and Effect of a Late HIV-Modified Vaccinia Virus Ankara Boost in Tanzanian Volunteers
Joachim A; Munseri PJ; Nilsson C; Bakari M; Aboud S; Lyamuya EF; Tecleab T; Liakina V; Scarlatti G; Robb ML; Earl PL; Moss B; Wahren B; Mhalu F; Ferrari G; Sandstrom E; Biberfeld G
Article: BMJ OPEN. 2017;7(7):e015653
Human papillomavirus prevalence and genotype distribution among young women and men in Maputo city, Mozambique
Omar VE; Orvalho A; Nalia I; Kaliff M; Lillsunde-Larsson G; Ramqvist T; Nilsson C; Falk K; Nafissa O; Vindorai JI; Andersson S
Article: HELIYON. 2017;3(6):e00339
HIVIS-DNA or HIVISopt-DNA priming followed by CMDR vaccinia-based boosts induce both humoral and cellular murine immune responses to HIV.
Hinkula J; Petkov S; Ljungberg K; Hallengärd D; Bråve A; Isaguliants M; Falkeborn T; Sharma S; Liakina V; Robb M; Eller M; Moss B; Biberfeld G; Sandström E; Nilsson C; Markland K; Blomberg P; Wahren B
Article: PLOS ONE. 2016;11(5):e0155702
Boosting with Subtype C CN54rgp140 Protein Adjuvanted with Glucopyranosyl Lipid Adjuvant after Priming with HIV-DNA and HIV-MVA Is Safe and Enhances Immune Responses: A Phase I Trial
Joachim A; Bauer A; Joseph S; Geldmacher C; Munseri PJ; Aboud S; Missanga M; Mann P; Wahren B; Ferrari G; Polonis VR; Robb ML; Weber J; Tatoud R; Maboko L; Hoelscher M; Lyamuya EF; Biberfeld G; Sandstrom E; Kroidl A; Bakari M; Nilsson C; McCormack S
Article: PLOS ONE. 2015;10(4):e0119629
Priming with a Simplified Intradermal HIV-1 DNA Vaccine Regimen followed by Boosting with Recombinant HIV-1 MVA Vaccine Is Safe and Immunogenic: A Phase IIa Randomized Clinical Trial
Munseri PJ; Kroidl A; Nilsson C; Joachim A; Geldmacher C; Mann P; Moshiro C; Aboud S; Lyamuya E; Maboko L; Missanga M; Kaluwa B; Mfinanga S; Podola L; Bauer A; Godoy-Ramirez K; Marovich M; Moss B; Hoelscher M; Gotch F; Stoehr W; Stout R; McCormack S; Wahren B; Mhalu F; Robb ML; Biberfeld G; Sandstrom E; Bakari M
Article: PLOS ONE. 2015;10(4):e0118486
Potent Functional Antibody Responses Elicited by HIV-I DNA Priming and Boosting with Heterologous HIV-1 Recombinant MVA in Healthy Tanzanian Adults
Joachim A; Nilsson C; Aboud S; Bakari M; Lyamuya EF; Robb ML; Marovich MA; Earl P; Moss B; Ochsenbauer C; Wahren B; Mhalu F; Sandstrom E; Biberfeld G; Ferrari G; Polonis VR
Article: PLOS ONE. 2015;10(6):e0131748
HIV-DNA Given with or without Intradermal Electroporation Is Safe and Highly Immunogenic in Healthy Swedish HIV-1 DNA/MVA Vaccinees: A Phase I Randomized Trial
Nilsson C; Hejdeman B; Godoy-Ramirez K; Tecleab T; Scarlatti G; Brove A; Earl PL; Stout RR; Robb ML; Shattock RJ; Biberfeld G; Sandstrom E; Wahren B
Article: PLOS ONE. 2015;10(3):e0121452
Incidence of HIV and the Prevalence of HIV, Hepatitis B and Syphilis among Youths in Maputo, Mozambique: A Cohort Study
Viegas EO; Tembe N; Macovela E; Goncalves E; Augusto O; Ismael N; Sitoe N; De Schacht C; Bhatt N; Meggi B; Araujo C; Sandstrom E; Biberfeld G; Nilsson C; Andersson S; Jani I; Osman N
Article: CLINICAL AND VACCINE IMMUNOLOGY. 2014;21(3):391-398
Performance of a redesigned HIV Selectest enzyme-linked immunosorbent assay optimized to minimize vaccine-induced seropositivity in HIV vaccine trial participants.
Penezina O; Krueger NX; Rodriguez-Chavez IR; Busch MP; Hural J; Kim JH; O'Connell RJ; Hunter E; Aboud S; Higgins K; Kovalenko V; Clapham D; Crane D; Levin AE; HIV Selectest Study Group
Article: AIDS RESEARCH AND HUMAN RETROVIRUSES. 2014;30(3):299-311
Broad and Potent Cellular and Humoral Immune Responses After a Second Late HIV-Modified Vaccinia Virus Ankara Vaccination in HIV-DNA-Primed and HIV-Modified Vaccinia Virus Ankara-Boosted Swedish Vaccinees
Nilsson C; Godoy-Ramirez K; Hejdeman B; Brave A; Gudmundsdotter L; Hallengard D; Currier JR; Wieczorek L; Hasselrot K; Earl PL; Polonis VR; Marovich MA; Robb ML; Sandstrom E; Wahren B; Biberfeld G
Article: PLOS ONE. 2014;9(5):e97391
Reference Values for Clinical Laboratory Parameters in Young Adults in Maputo, Mozambique
Tembe N; Joaquim O; Alfai E; Sitoe N; Viegas E; Macovela E; Goncalves E; Osman N; Andersson S; Jani I; Nilsson C
Article: AIDS. 2012;26(18):2275-2284
Resistance to antibody neutralization in HIV-2 infection occurs in late stage disease and is associated with X4 tropism
Marcelino JM; Borrego P; Nilsson C; Familia C; Barroso H; Maltez F; Doroana M; Antunes F; Quintas A; Taveira N
Article: VACCINE. 2011;29(46):8417-8428
Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania
Bakari M; Aboud S; Nilsson C; Francis J; Buma D; Moshiro C; Aris EA; Lyamuya EF; Janabi M; Godoy-Ramirez K; Joachim A; Polonis VR; Brave A; Earl P; Robb M; Marovich M; Wahren B; Pallangyo K; Biberfeld G; Mhalu F; Sandstrom E
Article: CLINICAL AND VACCINE IMMUNOLOGY. 2010;17(7):1124-1131
Strong HIV-Specific CD4⁺ and CD8⁺ T-Lymphocyte Proliferative Responses in Healthy Individuals Immunized with an HIV-1 DNA Vaccine and Boosted with Recombinant Modified Vaccinia Virus Ankara Expressing HIV-1 Genes
Aboud S; Nilsson C; Karlen K; Marovich M; Wahren B; Sandstrom E; Gaines H; Biberfeld G; Godoy-Ramirez K
Article: JOURNAL OF MEDICAL VIROLOGY. 2009;81(12):1991-1998
Comparison of the Performance of Rapid HIV Tests Using Samples Collected for Surveillance in Mozambique
Melo J; Nilsson C; Mondlane J; Osman N; Biberfeld G; Folgosa E; Andersson S
Article: VACCINE. 2009;27(33):4468-4474
Recombinant Modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity
Gudmundsdotter L; Nilsson C; Brave A; Hejdeman B; Earl P; Moss B; Robb M; Cox J; Michael N; Marovich M; Biberfeld G; Sandstrom E; Wahren B
Article: AIDS. 2008;22(17):2257-2265
Envelope-specific antibody response in HIV-2 infection: C2V3C3-specific IgG response is associated with disease progression
Marcelino JM; Nilsson C; Barroso H; Gomes P; Borrego P; Maltez F; Rosado L; Doroana M; Antunes F; Taveira N
Article: VIROLOGY JOURNAL. 2008;5:96
HIV-2 neutralization by intact V3-specific Fab fragments
Sourial S; Nilsson C
Article: CLINICAL AND VACCINE IMMUNOLOGY. 2008;15(4):585-589
Optimal blood mononuclear cell isolation procedures for gamma interferon enzyme-linked immunospot testing of healthy Swedish and Tanzanian subjects
Nilsson C; Aboud S; Karlen K; Hejdeman B; Urassa W; Biberfeld G
Article: CURRENT HIV RESEARCH. 2006;4(2):229-237
Deletion of the V1/V2 region does not increase the accessibility of the V3 region of recombinant gp125
Sourial S; Nilsson C; Wärnmark A; Achour A; Harris RA
Article: MOLECULAR BIOTECHNOLOGY. 2005;30(2):155-162
Cloning, expression, and purification of HIV-2 gp125
Sourial S; Wärnmark A; Nilsson C; Björling E; Achour A; Harris RA
Article: JOURNAL OF GENERAL VIROLOGY. 2004;85(Pt 8):2407-2419
Enhanced cellular immunity and systemic control of SHIV infection by combined parenteral and mucosal administration of a DNA prime MVA boost vaccine regimen
Mäkitalo B; Lundholm P; Hinkula J; Nilsson C; Karlén K; Mörner A; Sutter G; Erfle V; Heeney JL; Wahren B; Biberfeld G; Thorstensson R
Article: JOURNAL OF VIROLOGY. 2004;78(13):7016-7022
Potent neutralizing serum immunoglobulin A (IgA) in human immunodeficiency virus type 2-exposed IgG-seronegative individuals
Qin LZ; Nilsson C; Sourial S; Andersson S; Larsen O; Aaby P; Ehnlund M; Björling E
Article: JOURNAL OF MEDICAL PRIMATOLOGY. 2004;33(1):16-24
Dichotomy between CD1a+ and CD83+ dendritic cells in lymph nodes during SIV infection of macaques
Söderlund J; Nilsson C; Loré K; Castanos-Velez E; Ekman M; Heiden T; Biberfeld G; Andersson J; Biberfeld P
Article: VIROLOGY. 2003;308(2):225-232
Serum immunoglobulin A (IgA)-mediated immunity in human immunodeficiency virus type 2 (HIV-2) infection
Qin LZ; Skott P; Sourial S; Nilsson C; Andersson S; Ehnlund M; Taveira N; Björling E
Article: CLINICAL AND EXPERIMENTAL IMMUNOLOGY. 2002;129(1):11-18
Spontaneous production of RANTES and antigen-specific IFN-γ production in macaques vaccinated with SHIV-4 correlates with protection against SIVsm challenge
Ahmed RKS; Mäkitalo B; Karlén K; Nilsson C; Biberfeld G; Thorstensson R
Article: JOURNAL OF GENERAL VIROLOGY. 2002;83(Pt 4):807-818
Immunization with recombinant modified vaccinia virus Ankara can modify mucosal simian immunodeficiency virus infection and delay disease progression in macaques
Nilsson C; Sutter G; Walther-Jallow L; ten Haaft P; Åkerblom L; Heeney J; Erfle V; Böttiger P; Biberfeld G; Thorstensson R
Article: JOURNAL OF GENERAL VIROLOGY. 2001;82(Pt 7):1601-1612
Cross-protection against mucosal simian immunodeficiency virus (SIVsm) challenge in human immunodeficiency virus type 2-vaccinated cynomolgus monkeys
Walther-Jallow L; Nilsson C; Söderlund J; ten Haaft P; Mäkitalo B; Biberfeld P; Böttiger P; Heeney J; Biberfeld G; Thorstensson R
Article: VACCINE. 2001;19(25-26):3526-3536
Enhanced simian immunodeficiency virus-specific immune responses in macaques induced by priming with recombinant Semliki Forest virus and boosting with modified vaccinia virus Ankara
Nilsson C; Mäkitalo B; Berglund P; Bex F; Liljeström P; Sutter G; Erfle V; ten Haaft P; Heeney J; Biberfeld G; Thorstensson R
Article: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2001;53(3):245-253
Role of CD8⁺ cell-produced anti-viral factors in protective immunity in HIV-2-exposed but seronegative macaques resistant to intrarectal SIVsm challenge
Ahmed RKS; Nilsson C; Biberfeld G; Thorstensson R
Article: VIROLOGY. 2000;278(2):400-411
Induction of immune responses and break of tolerance by DNA against the HIV-1 coreceptor CCR5 but no protection from SIVsm challenge
Zuber B; Hinkula J; Vödrös D; Lundholm P; Nilsson C; Mörner A; Levi M; Benthin R; Wahren B
Article: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2000;51(2):186-194
Recruitment of monocyte derived dendritic cells ex vivo from SIV infected and non infected cynomolgus monkeys
Söderlund J; Nilsson C; Ekman M; Walther L; Gaines H; Biberfeld G; Biberfeld P
Article: JOURNAL OF GENERAL VIROLOGY. 1999;80:1569-1574
β-chemokine production in macaques vaccinated with live attenuated virus correlates with protection against simian immunodeficiency virus (SIVsm) challenge
Ahmed RKS; Nilsson C; Wang YF; Lehner T; Biberfeld G; Thorstensson R
Article: AIDS. 1998;12(17):2261-2270
Live attenuated simian immunodeficiency virus (SIV)mac in macaques can induce protection against mucosal infection with SIVsm
Nilsson C; Mäkitalo B; Thorstensson R; Norley S; Binninger-Schinzel D; Cranage M; Rud E; Biberfeld G; Putkonen P
Article: NATURE MEDICINE. 1995;1(9):914-918
LONG-TERM PROTECTION AGAINST SIV-INDUCED DISEASE IN MACAQUES VACCINATED WITH A LIVE ATTENUATED HIV-2 VACCINE
PUTKONEN P; WALTHER L; ZHANG YJ; LI SL; NILSSON C; ALBERT J; BIBERFELD P; THORSTENSSON R; BIBERFELD G
Show more

All other publications

Corrigendum: MICROBIAL CELL FACTORIES. 2024;23(1):75
Stable expression of HIV-1 MPER extended epitope on the surface of the recombinant probiotic bacteria Escherichia Coli Nissle 1917 using CRISPR/Cas9 (vol 23, 39, 2024)
Ninyio N; Schmitt K; Sergon G; Nilsson C; Andersson S; Scherbak N
Published conference paper: JOURNAL OF INFECTIOUS DISEASES. 2008;198(10):1482-1490
Broad Immunogenicity of a Multigene, Multiclade HIV-1 DNA Vaccine Boosted with Heterologous HIV-1 Recombinant Modified Vaccinia Virus Ankara
Sandstrom E; Nilsson C; Hejdeman B; Brave A; Bratt G; Robb M; Cox J; VanCott T; Marovich M; Stout R; Aboud S; Bakari M; Pallangyo K; Ljungberg K; Moss B; Earl P; Michael N; Birx D; Mhalu F; Wahren B; Biberfeld G
Thesis / dissertation: 2001
HIV-2 and SIV vaccine studies in macaques : with emphasis on humoral immune responses
Nilsson, Charlotta

Employments

Affiliated to Research, Department of Laboratory Medicine, Karolinska Institutet, 2022-2025

Degrees and Education

Docent, Karolinska Institutet, 2015
Doctor Of Philosophy, Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, 2001

Articles

All other publications

Employments

Degrees and Education

News from KI

Events from KI